Kurhanewicz, J <br/><br/>
Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials.  [electronic resource] 

 -  Urology  Apr 2001 
 - 124-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review 
<br/><br/><label>ISSN: </label>1527-9995 
<br/><br/><label>Standard No.: </label>10.1016/s0090-4295(00)00955-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Citric Acid--metabolism<br/>Humans<br/>Magnetic Resonance Imaging<br/>Magnetic Resonance Spectroscopy<br/>Male<br/>Neoplasm Proteins--metabolism<br/>Patient Selection<br/>Prostate--pathology<br/>Prostate-Specific Antigen--metabolism<br/>Prostatic Neoplasms--diagnosis